Ascidian Therapeutics
John F. Kerwin is an experienced professional in the field of gene therapy and biopharmaceuticals, currently serving as VP and Head of Technical Development at Ascidian Therapeutics since May 2024. Prior to this role, John worked at Resilience from October 2020 to May 2024 as Technical Head of the Gene Therapy Franchise, overseeing technical development for viral vector R&D and CMC. John's previous positions include Global Lead for Gene Therapy Manufacturing Sciences at Biogen and Assistant Program Director at the Biotechnology Research and Education Program at the University of Maryland, where expertise in AAV and viral vector processes was honed. John has also worked as an independent consultant, providing specialized insights into CMC processes for AAV vectors. Academic credentials include a Bachelor of Science and a PhD in Chemical and Biomolecular Engineering from the University of Maryland.
This person is not in any teams
This person is not in any offices
Ascidian Therapeutics
2 followers
Gene therapy is entering a new era as the field moves forward. But current technologies cannot overcome the challenges of many diseases. Ascidian’s unique approach aims to unlock these doors and enable treatment for millions of patients worldwide.